Tscan Therapeutics, Inc. · NASDAQ:TCRX
Tscan Therapeutics — Investor Presentation (January 2026)
36 slides from Tscan Therapeutics's investor presentation, Jan 12, 2026
Slide 1: Corporate Presentation January 2026
Corporate Presentation January 2026 Exhibit 99.1
Slide 2: Disclaimers and forward-looking statements
Disclaimers and forward-looking statements This presentation and the accompanying discussion contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding the Company’s plans, prog
Slide 3: TScan is a fully integrated, next-generation TCR-T cell therapy company
TScan is a fully integrated, next-generation TCR-T cell therapy company HEME MALIGNANCY PROGRAM Targets residual disease to prevent relapse in patients undergoing bone marrow transplant Promising data for TSC-101: Favorable RFS and OS compared to the control-arm with no DLTs. Durable responses with
Slide 4: Promising pipeline across multiple therapeutic areas
Promising pipeline across multiple therapeutic areas HLA type Indications Targets HLA-A*02:01 HLA-A*02:01 HLA-B*07:02 HLA-A*02:01 HLA-A*01:01 TSC-101 (HA-2) HEMATOLOGIC MALIGNANCIES SOLID TUMORS AML, MDS NSCLC, Sarcoma, Head & Neck, Cervical, Anal & Genital Autoimmunity IND-enabling Phase 1 Pivotal
Slide 5: 2026 will be a transformational year for TScan
2026 will be a transformational year for TScan Aligned on final pivotal design for TSC-101 Two-year relapse data from initial TSC-101 patients Heme Program File two INDs for TSC-102 (A*03:01 and A*01:01) in Q1 Opened expansion cohorts at DL3 Auto-immunity Identified novel autoantigens Presented prec
Slide 6: Heme Malignancies: Targeting residual disease to prevent relapse
Heme Malignancies: Targeting residual disease to prevent relapse in patients undergoing allogeneic HCT
Slide 7: TScan is working to treat residual disease and prevent relapse in heme malignancies
TScan is working to treat residual disease and prevent relapse in heme malignancies Current Standard of Care Unmet Medical Need TScan Approach Allogeneic hematopoietic cell transplant (Allo-HCT) is the only potential cure for patients with AML and MDS 38-44% of patients relapse within two years foll
Slide 8: TSC-101 is a TCR-T cell therapy designed to eliminate residual cancer
TSC-101 is a TCR-T cell therapy designed to eliminate residual cancer and prevent relapse following Allo-HCT TSC-101 PATIENT TSC-101 DONOR Hematopoietic cell transplant Cancer cell Normal blood cell Stem cell T cell HA-2 positive HA-2 negative HA-2 negative HA-2 positive TSC-101 Residual cancer Stem
Slide 9: ALLOHA Phase 1 trial for TSC-101 in AML, ALL, and MDS
ALLOHA™, a multi-arm Phase 1 trial for TSC-101 in subjects with AML, ALL, and MDS (NCT05473910) HCT Pre-transplant screening Endpoint and safety monitoring RIC Day 0 Day +21 Day +61 Donor screening Manufacturing apheresis HCT apheresis TSC-101 Infusion 1 TSC-101 Infusion 2 Subject screening Control
Slide 10: Patients in both arms are at high risk for relapse
Patients in both the treatment and control arms are at high risk for relapse TSC-101 Control Enrolled Subjects 23 19 Evaluable Subjects* 19 (100%) 18 (100%) Median Time from HCT, months 13.4 (4-33) 16.1 (1-36) Age, Median (Range) 65 (52-74) 66 (23-77) Sex, Male %) 13 (68%) 9 (50%) Underlying Disease
Slide 11: TSC-101 is well tolerated with no dose-limiting toxicity
TSC-101 is well tolerated with no dose-limiting toxicity TSC-101 n=19 Control n=18 Treatment-emergent aGvHD (MAGIC) 12 (63%) 10 (56%) Grade I 8 (42%) 5 (28%) Grade II 3 (16%) 4 (22%) Grade III 1 (5%) 1 (6%) Grade IV 0 (0%) 0 (0%) Any Treatment-emergent cGvHD (NIH) 1 (5%) 2 (11%)
Slide 12: Use of TSC-101 shows fewer relapses, more durable remissions, longer survival
Use of TSC-101 shows fewer relapses, more durable remissions, and longer survival MDS MDS MDS AML AML AML AML AML AML MDS MDS AML Control-1 Control-2 Control-3 Control-7 Control-8 Control-5 Control-4 Control-6 Control-9 Control-10 Control-11 Control-12 Control-13 AML AML Control-14 AML Control-15 AL
Slide 13: TSC-101 continues to show strong activity by chimerism assays
TSC-101 continues to show strong activity by chimerism assays DL1 DL2s‡ DL2 DL3s‡ DL3 DL3 DL3 DL3 DL3 DL3 DL3 DL3 DL3 DL3/4 DL4 DL3/4 DL4 DL4 DL4 C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 C13 C14 C15 C16 MDS AML B-ALL B-ALL MDS AML AML MDS AML AML AML AML MDS AML AML AML AML MDS AML MDS MDS MDS AML AML
Slide 14: TSC-101 infusion post-relapse converted subject to complete donor chimerism
TSC-101 infusion post-relapse converted subject to complete donor chimerism and complete remission Recipient chimerism (%) 74-year-old male with AML in CR1 received 2 infusions of TSC-101 per DL3 2nd infusion was delayed by 36 days due to treatment of aGvHD At time of relapse, received 370 M cells w
Slide 15: Updated ALLOHA Phase 1 data support launch of pivotal trial in Q2 2026
Recently updated ALLOHA™ Phase 1 data support launch of pivotal trial in Q2 2026 Infusions with TSC-101 were well-tolerated with no DLTs and adverse events following HCT + TSC-101 were consistent with HCT alone Durable responses with 100% (3/3) of patients 2-years post-HCT showing detectable TSC-101
Slide 16: Heme Development Strategy
Heme Development Strategy Targeting residual disease to prevent relapse in patients undergoing allogeneic HCT
Slide 17: Pivotal trial design for TSC-101 uses a biologically-assigned control arm
Pivotal trial design for TSC-101 uses a biologically-assigned control arm to support relapse-free survival as the primary endpoint Biological assignment Company has reached agreement with the FDA to use a pivotal trial design that mirrors the ALLOHA™ Phase 1 trial (NCT05473910) All patients that are
Slide 18: Commercial opportunity: Clear unmet need with concentrated market
Commercial opportunity: Clear unmet need with concentrated market and a broad range of expansion opportunities
Slide 19: Commercial-ready TCR-T from healthy donor cells with streamlined operations
TCR-T cells engineered from healthy donor T cells, resulting in more consistent product Allogeneic therapy allows for manufacturing to be completed prior to ideal infusion time Global CDMO engaged for scaled-up manufacturing; initial tech transfer completed TSC-101 is used with current SOC transplan
Slide 20: TSC-101 delivers a streamlined, predictable treatment journey
TSC-101 delivers a streamlined, predictable, and easily planned treatment journey * Infusion 1 & 2 site of care (inpatient vs outpatient) determined by administering physician. Infusion 1 may be given upon engraftment and between days 14-35 post transplant, infusion 2 would be administered about 40
Slide 21: Commercial-ready manufacturing process requires less ex vivo T-cell expansion
Commercial-ready manufacturing process requires less ex vivo T-cell expansion Symbols: mean +/- standard error; *p<0.05. Mixed chimerism or relapse (n=6) Complete Chimerism (n=14) New process (n=2) Fold expansion (Day 9 to harvest) New commercial-ready process reduces manufacturing time by 5 days (1
Slide 22: Developing a top tier go-to-market strategy
Developing a top tier go-to-market strategy Targeting ~40 authorized treatment centers at launch Currently ~60% of all allo transplants in the U.S. occur at the targeted ATCs Sales Force Market Access Dedicated team acting as direct partners to key centers, providing focused support and seamless lau
Slide 23: TSC-101 could generate $1 billion+ annually at peak penetration in the U.S.
TSC-101 could generate $1 billion+ annually at peak penetration in the U.S. $1.4B+ peak revenue Price benchmarked to current cell therapies 6,200 AML/MDS patients undergoing Allo HCT 2,600 HLA-A*02:01 positive patients (42%) ~2,100 with A*02-negative donor (80%) Addressable U.S. Patient Population a
Slide 24: TScan is targeting the most frequent HLAs to address a broad patient population
A*03:01 A*01:01 A*24:02 HLA Total 1.1k (22%) 1.2k (24%) 800 (17%) 3.9k (~78%) 1.8k (25%) 2.0k (26%) 1.4k (19%) 6.8k (~83%) 550 (7%) 1.1k (14%) 3.0k (37%) 4.0k (~50%) 3.5k 4.3k 5.2k 15.1k A*02:01 2.1k (42%) 3.9k (47%) 1.5k (19%) 7.7k TScan is targeting the most frequent human leukocyte antigens (HLAs
Slide 25: Expansion opportunities to reach about 20k AML and MDS patients
Expansion opportunities for the program provide a way to reach about 20k AML and MDS patients in North America, Europe, and APAC Capturing an expanding treatment landscape: Expansion driven by launch of products for additional HLA types.* Plan to file INDs for TSC-102-A0301 and TSC-102-A0101 in 1Q 2
Slide 26: Heme Program Progress and Anticipated Milestones
Heme Program Progress and Anticipated Milestones Reached agreement with FDA on pivotal trial design Transferred commercial-ready manufacturing process to external CDMO File INDs for TSC-102-A0301 and TSC-102-A0101 Q1 2026 Launch pivotal study for TSC-101 in Q2 2026 Two-year relapse data from initial
Slide 27: Solid Tumors
Solid Tumors Developing multiplex TCR-T therapy to overcome tumor heterogeneity
Slide 28: Multiplex TCR-T therapy designed to overcome heterogeneity of solid tumors
Multiplex TCR-T therapy designed to overcome the heterogeneity of solid tumors Relapse Targeting long-term remission or cure Many solid tumors exhibit heterogeneity of target expression NSCLC Single solid tumor expression of PRAME and MAGE-A4 MAGE-A4+ Singleplex TCR-T targeting PRAME Multiplex TCR-T
Slide 29: TScan is building the ImmunoBank of TCRs
TScan is building the ImmunoBank of TCRs to enable multiplex TCR-T cell therapy Customized TCR-T cell therapy Cancer cells with different HLA types and targets T cells Cancer patient Profile tumor HLA Type ImmunoBank of therapeutic TCRs HLAs Targets Determine HLA type and target expression in patien
Slide 30: Phase 1 PLEXI-T study design
Tumor testing for target and testing for HLA loss Patient selection Infusions 1a +1b Infusions 2a +2b Subject screening with germline HLA testing Treatment Protocol Screening Protocol ClinicalTrials.gov Identifier: NCT05973487; LD: lymphodepletion with fludarabine x 4 days and cyclophosphamide x 3 d
Slide 31: Lentiviral in vivo technology addresses challenges of autologous TCR-T
Lentivirus Lentiviral in vivo technology addresses the key challenges of autologous TCR-T In vivo engineering solves the key challenges of autologous TCR-T approaches Lymphodepletion is not required Off-the-shelf (no patient-specific manufacturing); lentivirus prepared in large batches with signific
Slide 32: Autoimmunity
Autoimmunity Deploying TargetScan platform to discover novel T-cell targets in autoimmune disorders
Slide 33: Autoimmunity represents an area of unmet need with few validated targets
Autoimmunity represents an exciting area of unmet need with few validated targets TScan’s target discovery platform provides a way to identify targets in autoimmune disease, unlocking the development of targeted therapeutics Current therapies typically provide general immune suppression, leading to
Slide 34: TargetScan platform can identify shared autoantigens
TargetScan platform can be used to identify the shared autoantigens driving T-cell mediated autoimmune diseases, enabling development of first-in-class drugs Multi-year collaboration using TargetScan to identify targets for T cells in patients with Crohn’s disease Identified targets for systemic scl
Slide 35: 2026 will be a transformational year for TScan
2026 will be a transformational year for TScan Aligned on final pivotal design for TSC-101 Two-year relapse data from initial TSC-101 patients Heme Program File two INDs for TSC-102 (A*03:01 and A*01:01) in Q1 Opened expansion cohorts at DL3 Auto-immunity Identified novel autoantigens Presented prec
Slide 36: Thank You
THANK YOU
TScan Therapeutics — Investor Presentation (January 2026) on 6ix